1-3 of 3
Jason Howe
Close
Sort by
Journal Articles

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

David S. Siegel, MD, PhD, Meletios Athanasios Dimopoulos, MD, Sung-Soo Yoon, MD, PhD, Jacob P. Laubach, MD, Jonathan L. Kaufman, MD, Hartmut Goldschmidt, MD, Donna E. Reece, MD, FRCPC, Xavier Leleu, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Fritz C. Offner, MD, PhD, Michele Cavo, MD, Arnon Nagler, MD, Sundar Jagannath, MD, Thorsten Graef, MD, PhD, Jennifer Houp, Linda Sun, PhD, Jason Howe, Sandra M. Wear, RN, Kenneth C. Anderson, MD
Journal: Blood
Blood (2011) 118 (21): 480.
https://doi.org/10.1182/blood.V118.21.480.480
Published: 2011
Journal Articles

Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study.

David Siegel, Donna M Weber, MD, Constantine S. Mitsiades, Meletios A. Dimopoulos, Jean-Luc Harousseau, Syed Rizvi, Jason Howe, David Reiser, Catriona Byrne, Kenneth C. Anderson, MD, Paul Richardson, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 305.
https://doi.org/10.1182/blood.V114.22.305.305
Published: 2009
Journal Articles

A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

David Siegel, Donna Weber, MD, Constantine S. Mitsiades, MD, PhD, Syed Rizvi, Jose Garcia-Vargas, Jason Howe, David Reiser, Kenneth C. Anderson, MD, Paul Richardson, MD
Journal: Blood
Blood (2008) 112 (11): 3705.
https://doi.org/10.1182/blood.V112.11.3705.3705
Published: 2008